Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This article reviews finasteride's potential side effects, notably post-finasteride syndrome, and suggests that hand preference and sexual orientation might predict these adverse effects, but it reports no clinical results.

This study reported that solid lipid nanoparticles of finasteride decorated with chitosan enhanced drug retention in skin layers, suggesting potential application in treating androgenic alopecia and benign prostate hyperplasia with fewer side effects.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

This study developed and validated a simple, cost-effective UV–Visible spectrophotometric method for estimating finasteride in pharmaceuticals, demonstrating good linearity, accuracy, precision, and sensitivity according to ICH guidelines, making it suitable for routine quality control.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

This study suggests that 9-Octadecenoic acid (Z)-, 2,3-dihydroxypropyl ester from African Yam bean seeds may inhibit the human 5α-reductase II enzyme, potentially helping manage BPH, although further studies are needed.

In this study, the authors concluded that there is no clear difference in suicidal ideation between different 5α-reductase inhibitors, but results vary by finasteride dose, patient age, and psychiatric history.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

This review discusses the integration of modern and Unani medicine in the management of Benign Prostatic Hyperplasia, highlighting the potential of Unani herbal formulations as promising alternatives with minimal side effects but reports no new clinical results.

This in-silico study found that Finasteride interferes with neurotransmitters and may increase psychopathology when it decomposes into a carboxylic acid similar to Cortisol.

In this study, the n-hexane fraction of Carthamus oxyacantha methanolic extract exhibited significant 5α-reductase inhibitory activity in vitro, suggesting potential therapeutic use for benign prostatic hyperplasia through DHT inhibition.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This study found that Sonirid Duo, a combination of tamsulosin and finasteride, significantly improved symptoms and quality of life in patients with BPH over 12 months.

In this study, the use of finasteride in young patients may be linked to a higher risk of anxiety, depression, and suicide-related adverse events.

This editorial discusses the potential progression of voiding symptoms over time in men, focusing on benign prostatic hyperplasia, but reports no new research findings.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

In this study, amputees in Shanghai with amputation stump skin disease experienced severely reduced quality of life, with fungal infections and extended prosthetic wear identified as significant risk factors.

Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.

This consensus summary suggests that 5-alpha reductase inhibitors have clear benefits for benign prostatic hyperplasia, but their impact on prostate cancer prevention is still debated.

This narrative review discusses adverse effects associated with 5-ARI treatments for male-pattern baldness and benign prostate hyperplasia, including sexual health, neurological, endocrine, metabolic, and cardiovascular impacts, and emphasizes careful prescription assessment.

This study found that the methanolic extract of Hibiscus rosa sinensis exhibits promising 5α-reductase inhibitory activity, suggesting its potential use in the treatment of androgenic conditions like male pattern hair loss and benign prostatic hyperplasia.

This review highlights the use of finasteride, a 5alpha-reductase inhibitor, for treating benign prostatic hyperplasia and male pattern hair loss, noting that it may cause male sexual dysfunction but usually with tolerable side effects that decrease over time, not requiring treatment discontinuation.

Tamsulosin works faster, but both drugs have similar effects after 6 months.